### Highlights of This Issue  5145

#### SPECIAL FEATURES

**CCR Translations**

- **5147** Blocking Immunosuppressive Checkpoints for Glioma Therapy: The More the Merrier!
  - Maria G. Castro, Gregory J. Baker, and Pedro R. Lowenstein
  - *See related article, p. 5290*

**CCR New Strategies**

- **5150** New Strategies in Ovarian Cancer: Translating the Molecular Complexity of Ovarian Cancer into Treatment Advances
  - Joyce Liu and Ursula A. Matulonis

**Molecular Pathways**

- **5157** Molecular Pathways: Myeloid Complicity in Cancer
  - Ingunn M. Stromnes, Philip D. Greenberg, and Sunil R. Hingorani

**CCR Focus**

- **5172** The Lymphoma Medicine Cabinet
  - Susan E. Bates

- **5173** Putting the Clinical and Biological Heterogeneity of Non-Hodgkin Lymphoma into Context
  - Owen A. O’Connor and Kensei Tobinai

- **5182** Precision Treatment of Distinct Molecular Subtypes of Diffuse Large B-cell Lymphoma: Ascribing Treatment Based on the Molecular Phenotype
  - Kieron Dunleavy, Mark Roschewski, and Wyndham H. Wilson

- **5194** New Paradigms in Mantle Cell Lymphoma: Is It Time to Risk-Stratify Treatment Based on the Proliferative Signature?
  - Martin Dreyling, Simone Ferrero, Niklas Vogt, and Wolfram Klappler on behalf of the European Mantle Cell Lymphoma Network

- **5207** Emerging Role of Infectious Etiologies in the Pathogenesis of Marginal Zone B-cell Lymphomas
  - Emanuele Zucca, Francesco Bertoni, Barbara Vannata, and Franco Cavalli

- **5217** Human T-cell Lymphotropic Virus Type I-Associated Adult T-cell Leukemia–Lymphoma: New Directions in Clinical Research
  - Kunihiro Tsukasaki and Kensei Tobinai

- **5226** Are We Nearing an Era of Chemotherapy-Free Management of Indolent Lymphoma?
  - Emmanuel Bachy and Gilles Salles

- **5240** Changing the Paradigms of Treatment in Peripheral T-cell Lymphoma: From Biology to Clinical Practice
  - Owen A. O’Connor, Govind Bhagat, Karthik Ganapathi, Martin Bjerregaard Pedersen, Francesco D’Amore, Dejan Radeski, and Susan E. Bates

#### CANCER THERAPY: CLINICAL

- **5255** A Phase I Study of the First-in-Class Antimitochondrial Metabolism Agent, CPI-613, in Patients with Advanced Hematologic Malignancies
  - Timothy S. Pardoe, King Lee, John Luddy, Claudia Matteo, Robert Rodriguez, Scott Isom, Lance D. Miller, Kristin M. Stadelman, Denise Levitan, David Hurd, Leslie R. Ellis, Robin Harrelson, Megan Manuel, Sarah Dralle, Susan Lyerly, and Bayard L. Powell

#### PERSONALIZED MEDICINE AND IMAGING

- **5265** Gene Signature–Guided Dasatinib Therapy in Metastatic Breast Cancer
  - Lajos Pusztai, Stacy Moulder, Mehmet Altan, Danielle Kwiatkowski, Vicente Valero, Naoto T. Ueno, Francisco J. Esteva, Rony Avritscher, Yuan Qi, Lewis Strauss, Gabriel N. Hortobagyi, Christos Hatzis, and W. Fraser Symmans
## Table of Contents

### Development and Validation of a Gene Profile Predicting Benefit of Postmastectomy Radiotherapy in Patients with High-Risk Breast Cancer: A Study of Gene Expression in the DBCG82bc Cohort
Trine Tramm, Hayat Mohammed, Simen Myhre, Marianne Kyndt, Jan Alsner, Anne-Lise Borresen-Dale, Therese Sørlie, Arnoldo Frigessi, and Jens Overgaard

### Pharmacogenomic Modeling of Circulating Tumor and Invasive Cells for Prediction of Chemotherapy Response and Resistance in Pancreatic Cancer
Kenneth H. Yu, Mark Ricigliano, Manuel Hidalgo, Ghassan K. Abou-Alfa, Maeye A. Lowery, Leonard B. Saltz, Joseph F. Crotty, Kristen Gary, Brandon Cooper, Rena Lapidus, Mariola Sadowska, and Eileen M. O'Reilly

### Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors
Derek A. Wainwright, Alan L. Chang, Mahua Dey, Irina V. Balyasnikova, Chung Kwon Kim, Alex Tobias, Yu Cheng, Julius W. Kim, Jian Qiao, Lingjiao Zhang, Yu Han, and Maciej S. Lesniak

### Overdetection of Recurrence after Radical Prostatectomy: Estimates Based on Patient and Tumor Characteristics
Jing Xia, Bruce J. Trock, Roman Gulati, Leslie Mallinger, Matthew R. Cooperberg, Peter R. Carroll, H. Ballentine Carter, and Ruth Etzioni

### Identification of Differentially Expressed Long Noncoding RNAs in Bladder Cancer
Stefan Peter, Edyta Borkowska, Ross M. Drayton, Callum P. Rakhit, Aidan Noon, Wei Chen, and James WF Catto

### Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies

### Smoking and Risk of Low- and High-Grade Prostate Cancer: Results from the REDUCE Study
Tammy Ho, Lauren E. Howard, Adriana C. Vidal, Leah Gerber, Daniel Moreira, Madeleine McKeever, Gerald Andriole, Ramiro Castro-Santamaria, and Stephen J. Freedland

### Correction
**Correction: Targeting miR21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth**
ABOUT THE COVER

The cover shows the expression of long noncoding RNAs in normal and malignant bladder urothelium as detected by microarray. Unsupervised hierarchical clustering reveals discrimination of normal, low-grade and high-grade malignant tissues. For details, see the article by Peter and colleagues on page 5311 of this issue.
Clinical Cancer Research

20 (20)


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/20/20

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.